CORE--MUCOSAL IMMUNITY

粘膜淋巴组织的使用在新兴的艾滋病毒研究中至关重要，因为 研究表明，淋巴组织的关键重要性是 复制HIV-1病毒的主要宿主。最近的研究已经开始解决 淋巴组织和非淋巴组织中CD4+T细胞耗尽率的差异 外周血，尝试比较淋巴组织中的病毒载量 和血浆。这些研究具有直接的临床意义 继续治疗。肠道相关淋巴组织(GALT) 代表身体的主要淋巴器官，其中大部分是直接的， 通过内窥镜活检可以快速、安全地获取。此外， 粘膜淋巴组织是免疫学的第一线。 防御，在更有组织的免疫学第二阶段之前 淋巴结和扁桃体组织的加工中心。重要的是这一点 粘膜组织被迅速替换，并可以频繁地进行评估，在 相比之下，淋巴结的数量有限，限制了它们在 监测组织反应。 新的粘膜免疫学核心将致力于为感兴趣的研究人员 来自胃肠道的临床特征良好的组织样本 用于研究的粘膜部位。从临床角度来看，这将涉及到 研究设计中的咨询，招募适当的患者队列， 协助提交个性化的人体主体保护 申请。实验室部分将提供优化的技术 在提供艾滋病毒血清阳性受试者的新鲜和冷冻样本以及 血清阴性对照。 在临床试验中很容易从患者身上收集样本，这将 允许评估病毒影响，例如，在暴露之前和之后 新的药物治疗方案。特定部位的活组织检查可用于 食道、胃、十二指肠、回肠、结肠和直肠的检查 组织。单细胞采集，如单核粘膜制剂 用于流式细胞术，或唾液或直肠免疫球蛋白分泌物 可以在前瞻性的基础上收集感兴趣的粘膜 调查人员。 其他粘膜部位(咽部、肺部、阴道、泌尿系)和 其他患者群体(包括妇女和少数族裔)将 可通过支持性临床医生网络获得。

The use of mucosal lymphoid tissue is critical in emerging HIV research as studies have demonstrated the pivotal importance of lymphoid tissue has a major reservoir of replicative HIV-1. Recent studies have begun to address the differential rates of CD4+ T cell depletion in lymphoid tissue and peripheral blood with attempts to compare viral burden in lymphoid tissue and plasma. These studies have immediate clinical implications regarding continuation of therapy. The gut-associated lymphoid tissue (GALT) represents the body's major lymphoid organ, most of which is directly, quickly and safely accessible by endoscopic biopsy. In addition, the mucosal lymphoid populations are among the first lines of immunological defense, preceding the second phase of more organized immunological processing centers of lymph nodes and tonsillar tissue. Importantly this mucosal tissue is rapidly replace and can be evaluated frequently, in contrast to lymph nodes which are finite in number limiting their use in monitoring tissue response. The new Mucosal Immunology Core will aim to provide interested researchers with clinically well-characterized tissue samples from gastrointestinal mucosal sites for study. From a clinical perspective, this will involve consultation in study design, recruitment of appropriate patient cohorts, assistance in submission of individualized human subjects protection applications. The laboratory component will provide optimized techniques in providing fresh and frozen samples of HIV seropositive subjects and seronegative controls. Samples are easily collected from patients in clinical trials which would allow assessment of viral impact, for example, before and after exposure to new medication regimens. Site-specific biopsies can be obtained for investigations of esophageal, stomach, duodenal, ileal, colonic and rectal tissue. Single cell collections, such as mononuclear mucosal preparations for flow cytometry, or immunoglobulin secretions from saliva or rectal mucosa can be collected on a prospective basis for interested investigators. Other mucosal sites (pharyngeal, pulmonary, vaginal, urinary system) and other patient populations (including women and minorities) will be available through a network of supportive clinicians.